Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
2.46
+0.06 (2.50%)
Jul 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.42 - 2.60
52 week 1.65 - 5.70
Open 2.43
Vol / Avg. 54,314.00/73,981.00
Mkt cap 36.70M
P/E     -
Div/yield     -
EPS -6.78
Shares 15.23M
Beta 2.45
Inst. own 53%
Aug 8, 2017
Q2 2017 Orexigen Therapeutics Inc Earnings Call - 5:00pm GMT-4 - Add to calendar
Aug 8, 2017
Q2 2017 Orexigen Therapeutics Inc Earnings Release - 4:00pm GMT-4 - Add to calendar
Jul 7, 2017
Orexigen Therapeutics Inc Annual Shareholders Meeting (Estimated)
May 16, 2017
Orexigen Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 9, 2017
Q1 2017 Orexigen Therapeutics Inc Earnings Call - Webcast
May 9, 2017
Q1 2017 Orexigen Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -360.86% -72.75%
Operating margin -216.92% -114.76%
EBITD margin - -149.03%
Return on average assets -102.45% -9.07%
Return on average equity -1126.70% -54.24%
Employees 132 -
CDP Score - -

Address

3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Officers and directors

Patrick J. Mahaffy Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Jason A. Keyes Chief Financial Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Thomas R. Cannell Chief Operating Officer, Executive Vice President, President - Global Commercial Products
Age: 55
Bio & Compensation  - Reuters
Thomas P. Lynch Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Peter Flynn Ph.D. Senior Vice President, Head - Development, Regulatory Affairs and Safety
Age: 43
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 52
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 75
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 52
Bio & Compensation  - Reuters
Peter K. Honig M.D. M.P.H. Independent Director
Age: 60
Bio & Compensation  - Reuters